592 results on '"Finetti, Pascal"'
Search Results
2. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer
3. Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression
4. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
5. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
6. Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect
7. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
8. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC
9. BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells
10. Correction: The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
11. The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
12. EFA6B regulates a stop signal for collective invasion in breast cancer
13. The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
14. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma
15. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
16. The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps
17. ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines
18. ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
19. The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer
20. The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
21. An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity
22. RE: HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
23. Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)
24. Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation
25. Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype
26. Abstract P6-10-15: Targeting MARCKS in inflammatory breast cancer increased paclitaxel sensitivity
27. DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer
28. PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
29. Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer
30. The MonarchE trial: improving the clinical outcome in HR+/HER2− early breast cancer: recent results and next steps.
31. Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer.
32. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer
33. First-in-Human, Phase I Study of PCA062 in Solid Tumors—Letter
34. A Lesson in Transcriptional Plasticity: Classical Identity Is Silenced, but Not Lost, in Pancreatic Ductal Adenocarcinoma Cell Lines
35. Genomic profiling of inflammatory breast cancer: A review
36. MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer
37. The serine/threonine kinase MINK1 directly regulates the function of promigratory proteins
38. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT
39. CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
40. A mechanistic model for prediction of metastatic relapse in early-stage breast cancer using routine clinical features
41. Low cholesterol biosynthesis favors epithelial‐to‐mesenchymal transition maintenance and influences tumor molecular subtyping and disease‐free survival in colon cancer patients
42. Abstract 2737: A mechanistic model for prediction of metastatic relapse in early-stage breast cancer using routine clinical features
43. Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate
44. Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial
45. Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity
46. Additional file 3 of CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
47. Additional file 6 of CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
48. Additional file 2 of CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
49. Additional file 5 of CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
50. Additional file 4 of CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.